Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention
- 1 December 2000
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 140 (6) , 834-839
- https://doi.org/10.1067/mhj.2000.110458
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Stenting for ischemic heart diseaseProgress in Cardiovascular Diseases, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stentingJournal of the American College of Cardiology, 1996
- Intracoronary Stenting Without Anticoagulation Accomplished With Intravascular Ultrasound GuidanceCirculation, 1995
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Angiographic Follow-up after Placement of a Self-Expanding Coronary-Artery StentNew England Journal of Medicine, 1991
- Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal AngioplastyNew England Journal of Medicine, 1987